1. Review recent pathophysiological findings in AD that have informed the selection of new therapeutic targets
2.Describe best practices for severity assessment and diagnosis of moderate-to-severe AD in pediatric patients, accounting for biomarkers, phenotype/genotype, comorbidities, and disease burden
3. Explain the mechanisms of action and clinical profiles of new and emerging targeted systemic agents for the long-term treatment of AD in pediatric patients
02/07/2019 - 12:00pm to 1:00pm CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Peter Lio, M.D.